Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
OwnerPramod K. Srivastavainventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising peptide-binding fragments of heat shock proteins (HSPs) and noncovalent complexes of peptide-binding fragments of HSPs in noncovalent association with antigenic molecules. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for the treatment and prevention of infectious diseases and cancer.
Claims46
A pharmaceutical composition comprising an amount of a molecular complex effective for treatment or prevention of an infectious disease or cancer, and a pharmaceutically acceptable carrier, said molecular complex comprising a heat shock protein peptide-binding fragment noncovalently associated with an antigenic molecule, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, and wherein said antigenic molecule displays the antigenicity of an antigen of an infectious agent or of a cancer cell.
A recombinant cell infected with a pathogen and transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, which heat shock protein peptide-binding fragment noncovalently associates with an antigenic molecule when said antigenic molecule is present, to form a complex that in sufficient amount is capable of eliciting an immune response to the antigenic molecule.
A recombinant cancer cell transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, which heat shock protein peptide-binding fragment noncovalently associates with an antigenic molecule when said antigenic molecule is present, to form a complex that in sufficient amount is capable of eliciting an immune response to the antigenic molecule.
A recombinant cell transformed with (i) a first nucleic acid comprising a first nucleotide sequence that is operably linked to a first promoter and that encodes a heat shock protein peptide-binding fragment a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, and (ii) a second nucleic acid comprising a second nucleotide sequence that is operably linked to a second promoter and encodes an antigenic molecule, such that the heat shock protein peptide-binding fragment and the antigenic molecule are expressed within the cell and noncovalently associate with each other to form a complex that in sufficient amount is capable of eliciting an immune response to the antigenic molecule.
A method for preparing a complex of a heat shock protein peptide-binding fragment noncovalently associated with a peptide, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, comprising:
- a) culturing cells, transformed with a nucleic acid comprising a nucleotide sequence encoding the heat shock protein peptide-binding fragment and operably linked to a promoter, under conditions such that the heat shock protein peptide-binding fragment is expressed by the cells and associates with peptides of the cells;
- and
- b) recovering a population of complexes of the heat shock protein peptide-binding fragment noncovalently associated with peptides from the cells.
A method for preparing a heat shock protein peptide-binding fragment noncovalently associated with peptides derived from one or more antigens of an infectious agent, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-termninal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-termninal side with y number of amino acids that naturally flank the peptide-binding domain on the C-termninal side, wherein x plus y is not more than 400, comprising:
- a) culturing infected cells, transformed with a nucleic acid comprising a nucleotide sequence encoding the heat shock protein peptide-binding fragment and operably linked to a promoter, under conditions such that the heat shock protein peptide-binding fragment is expressed by the cells and associates with peptides of the cells;
- and b) recovering from the cells a population of complexes of the heat shock protein peptide-binding fragment noncovalently associated with peptides derived from the infectious agent.
A method for preparing a complex of a heat shock protein peptide-binding fragment noncovalently associated with a peptide, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, said method comprising digesting a preparation of heat shock proteins noncovalently associated with peptides with a protease under conditions and for a length of time sufficient for the formation of peptide-binding fragments of the heat shock protein noncovalently associated with peptides.
A method for preparing a complex of a heat shock protein peptide-binding fragment noncovalently associated with a peptide, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, said method comprising:
- a) digesting a preparation of heat shock proteins with a protease under conditions and for a length of time sufficient for the formation of peptide-binding fragments of the heat shock protein;
- and
- b) contacting the peptide-binding fragments with peptides under conditions and for a length of time sufficient for the formation of complexes of heat shock protein peptide-binding fragments noncovalently associated with peptides.
A method for preparing in vitro complexes of heat shock protein peptide-binding fragments noncovalently associated with one or more antigenic molecules, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, said method comprising incubating a heat shock protein peptide-binding fragment and one or more antigenic molecules under conditions and for a length of time sufficient for the formation of the complexes.
A method of eliciting an immune response against an antigen in an individual comprising administering to the individual an immunogenic complex of a heat shock protein peptide-binding fragment noncovalently associated with a first antigenic molecule displaying antigenicity of the antigen, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400.
A method of treating or preventing an infectious disease in an individual having an infectious disease, or in whom prevention of an infectious disease is desired, comprising administering to the individual an immunogenic complex of a heat shock protein peptide-binding fragment noncovalently associated with a first antigenic molecule, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, wherein the first antigenic molecule displays the antigenicity of an antigen of an infectious agent of the infectious disease.
A method of treating or preventing an infectious disease in a subject having an infectious disease or in whom prevention of an infectious disease is desired comprising:
- a) culturing an infected cell transformed with a nucleic acid comprising a nucleotide sequence encoding a heat shock protein peptide-binding fragment, said infected cell displaying the antigenicity of an antigen of an infectious agent of the infectious disease, said heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, said nucleotide sequence being operably linked to a promoter, under conditions such that the peptide-binding fragment is expressed by the infected cells and associates with peptides of the cell;
- b) recovering complexes of the heat shock protein peptide-binding fragments noncovalently associated with peptides from the infected cell;
- and
- c) administering to the subject an amount of the recovered complexes effective to treat or prevent the infectious disease.
A method of treating or preventing an infectious disease in a subject having an infectious disease or in whom prevention of an infectious disease is desired comprising:
- a) culturing a recombinant cell transformed with (i) a first nucleic acid encoding a heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, and (ii) a second nucleic acid encoding an antigenic molecule displaying the antigenicity of an antigen of an infectious agent of the infectious disease;
- b) recovering complexes of the heat shock protein peptide-binding fragments noncovalently associated with the antigenic molecule;
- and
- c) administering to the subject an amount of the recovered complexes effective to treat or prevent the infectious disease.
A method of treating or preventing cancer in an individual having a type of cancer or in whom prevention of a type of cancer is desired comprising administering to the individual an immunogenic complex of a heat shock protein peptide-binding fragment noncovalently associated with a first antigenic molecule, said heat shock protein comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, wherein either (a) the first antigenic molecule displays antigenicity of said type of cancer or a metastasis thereof;
- or (b) the complex is obtained by recovering complexes from said type of cancer cells or a metastasis thereof that recombinantly express the heat shock protein peptide-binding fragment.
A method of treating or preventing cancer in a subject having a type of cancer or in whom prevention of a type of cancer is desired comprising:
- a) culturing a cancer cell transformed with a nucleic acid comprising a nucleotide sequence encoding a heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, said nucleotide sequence being operably linked to a promoter, under conditions such that the peptide-binding fragment is expressed by the cancer cell and associates with peptides of the cell;
- b) recovering complexes of the heat shock protein peptide-binding fragments noncovalently associated with peptides from the cancer cell;
- and
- c) administering to the subject an amount of the recovered complexes effective to treat or prevent cancer.
A method of treating or preventing cancer in a subject having a type of cancer or in whom prevention of a type of cancer is desired comprising:
- a) culturing a recombinant cell transformed with (i) a first nucleic acid encoding a heat shock protein peptide-binding fragment comprising a peptide-binding domain that is contiguous on the N-terminal side with x number of amino acids that naturally flank the peptide-binding domain on the N-terminal side, and that is contiguous on the C-terminal side with y number of amino acids that naturally flank the peptide-binding domain on the C-terminal side, wherein x plus y is not more than 400, and (ii) a second nucleic acid encoding an antigenic molecule displaying the antigenicity of an antigen of a cancer cell;
- b) recovering complexes of the heat shock protein peptide-binding fragments noncovalently associated with the antigenic molecule;
- and
- c) administering to the subject an amount of the recovered complexes effective to treat or prevent cancer.
Dependencies are inferred from the claim text.